Pfizer Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 09/27/2023
Pfizer Inc Stock Forecast and Price Target
The average target price for Pfizer Inc's stock set by eight renowned analysts in recent months is $52.65, representing a potential upside of approximately 62.6% from its last closing price if met by 2024. This estimation is based on a high estimate of $75.00 and a low estimate of $44.00. If you are looking to invest in the stock, it's important to research and compare different companies.
62.60% Upside
Pfizer Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Price has grown by 89.49%, from $36.70 to $69.54. 19 analysts predict Pfizer Inc's Fair Value will decrease by 2.33% in the next year, reaching $67.92. By 2030, professionals predict that Pfizer Inc's Fair Value will decrease by 42.04%, to $40.31.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$550.01 | Buy/Sell | $333.19 | -27.27% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$159.02 | Buy/Sell | $179.95 | 13.51% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.39 | Buy/Sell | $99.57 | 11.97% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$58.54 | Buy/Sell | $80.99 | 41.78% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$351.69 | Buy/Sell | $384.26 | -7.30% |
Pfizer Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Revenue has grown by 145.28%, from $40.91B to $100.33B. 17 analysts predict Pfizer Inc's Revenue will decrease by 20.35% in the next year, reaching $79.92B. By 2030, professionals predict that Pfizer Inc's Revenue will decrease by 47.10%, to $53.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$176.87 | Buy/Sell | $209.70 | 15.90% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$832.41 | Buy/Sell | $796.73 | -6.06% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.32 | Buy/Sell | $60.73 | 55.41% |
.jpg)
Pfizer Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Dividend per Share has grown from $1.44 to $1.64 – a 13.89% increase. Next year, analysts are expecting Dividend per Share to reach $1.68 – an increase of 2.44%. Over the next eight years, the forecast is for Dividend per Share to grow by 3.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$175.15 | Buy/Sell | $244.18 | 43.31% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.72 | Buy/Sell | $13.70 | 38.89% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$230.00 | Buy/Sell | $280.69 | 28.26% |
Pfizer Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Free Cash Flow has grown by 309684947.88%, rising from $10.54B to $32647.00T. The next year, 7 experts forecast that Pfizer Inc's Free Cash Flow will decrease by 100.00%, reaching $30.67B. In 2030, professionals predict that Pfizer Inc's Free Cash Flow will decrease by 100.00%, reaching $15.21B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent Inc | Hold |
15
|
$45.63 | Buy/Sell | $83.92 | 59.98% |
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$46.28 | Buy/Sell | $52.42 | 8.04% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.61 | Buy/Sell | $37.00 | 37.02% |
Pfizer Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Net Income has grown by 95.98%, rising from $16.03B to $31.41B. For next year, analysts predict Net Income of $31.82B, which would mean an increase of 1.32%. According to professionals, by 2030, Pfizer Inc's Net Income will have decreased by 40.08%, falling down to $18.82B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$123.57 | Buy/Sell | $163.67 | 32.72% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$29.98 | Buy/Sell | $62.67 | 100.13% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$8.77 | Buy/Sell | $73.38 | 116.65% |
Pfizer Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's EBITDA has grown, rising from $13.86B to $43.64B – a growth of 214.92%. According to the 10 analysts polled, in the next year, Pfizer Inc's EBITDA will fall by 14.50%, reaching $37.31B. By 2030, professionals believe that Pfizer Inc's EBITDA will have decreased by 55.44%, falling to $19.44B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£21.64 | Buy/Sell | £3.79 | -78.10% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$33.20 | Buy/Sell | $79.67 | 134.94% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$32.47 | Buy/Sell | $0.00 | -9.15% |
Pfizer Inc EBIT Forecast for 2023 - 2025 - 2030
Pfizer Inc's EBIT has grown In the last two years, rising from $8.14B to $26.85B – a growth of 229.71%. In the next year, analysts believe that EBIT will reach $33.76B – an increase of 25.78%. By 2030, professionals believe that Pfizer Inc's EBIT will decrease by 19.82%, reaching $21.52B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.51 | Buy/Sell | $41.00 | -3.32% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$8.53 | Buy/Sell | $12.60 | 46.54% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | Buy/Sell | $35.50 | 13.11% |
Pfizer Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's EPS has grown by 89.49%, from $2.95 to $5.59. 19 analysts predict Pfizer Inc's EPS will decrease by 2.33% in the next year, reaching $5.46. By 2030, professionals predict that Pfizer Inc's EPS will decrease by 42.04%, to $3.24.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$60.21 | Buy/Sell | $195.43 | 163.25% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$148.91 | Buy/Sell | $170.08 | 17.52% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$58.47 | Buy/Sell | $104.00 | -2.51% |
.jpg)